Ashwini Maratha

Accomplished Medical Affairs professional with over 15 years of experience in Global Clinical Operations, Medical Strategy, and Medical Affairs. Expertise in driving end-to-end clinical trials, leading global strategies for rare diseases and vaccines, and integrating AI tools in healthcare management. Proven ability to lead cross-functional teams, manage stakeholders, and deliver cutting-edge medical communication and education programs. Seeking a leadership role to leverage expertise in creating impactful healthcare solutions.

• April 2023, Distinguished Faculty, Global Gaucher Leadership Forum, Amsterdam, Netherlands
• September 2021, Distinguished speaker award, International Symposium on 'Host genetic response in COVID pandemic times: A boon or a bane' Approaches for development of global COVID-19 vaccine strategies, India, https://youtu.be/MOoz3XbX4Oo
• November 2019, State Advisory Board Member (Honorary, life-time member), Department for Women, Children, Disabled and Senior Citizens, Government of Telangana, G.O.Rt.No.84
• November 2014, MRCG/HRB Clinical Post-Doctoral Fellowship in Rare Diseases (Galactosaemia), Ireland
• June 2014, Best oral paper, International Congress of Endocrinology, Chicago, USA
• November 2013, Marie-Curie Experienced Research Secondment award, EUFP7-Industry-Academia Partnerships Pathways (IAPP), Ireland
• October 2012, Enterprise Ireland Research Commercialization Fellowship, Ireland
• October 2011, Health Research Board of Ireland Post-Doctoral Fellowship, Ireland
• April 2011, Best poster award, British Endocrine Society Annual Meeting, Birmingham, UK
• March 2010, Best oral poster, 8th World Congress on Trauma, Shock, Inflammation and Sepsis, Munich, Germany
• September 2007, Doctoral Fellowship in Immunology award, Health Research Board of Ireland tri-institutional (NUIM, TCD and Queen’s University) PhD scholars’ program in Immunology, Ireland
• May 2006, University Gold Medal, MSc Biotechnology, Kakatiya University, India

• Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase 3 trial, https://www.medrxiv.org/content/10.1101/2021.06.30.21259439v1.full.pdf, COVAXIN Study Group (Dr. Ashwini Maratha)
• A multi-centre, post-marketing surveillance study of Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar TCV) in India, https://www.tandfonline.com/doi/epdf/10.1080/21645515.2021.1947761?needAccess=true
• Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early-stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial, https://journals.sagepub.com/doi/pdf/10.1177/1758835919864236
• Analysis of Inflammatory Cytokines in Pre-Diabetic Subjects, https://juniperpublishers.com/crdoj/pdf/CRDOJ.MS.ID.555647.pdf
• Analysis of inflammatory cytokine and TLR expression levels in Type 2 Diabetes with complications, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5550417/pdf/41598_2017_Article_7230.pdf
• A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5271313/pdf/pone.0169964.pdf
• Classical Galactosaemia and CDG, the N-Glycosylation Interface, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5509556/pdf/978-3-662-55586-6_Chapter_5.pdf
• Classical galactosaemia: novel insights in IgG N-glycosylation and N-glycan biosynthesis, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070905/pdf/ejhg2015254a.pdf
• IgG N-Glycosylation Galactose Incorporation Ratios for the Monitoring of Classical Galactosaemia, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864864/pdf/978-3-662-50409-3_Chapter_490.pdf
• Acute serum amyloid A is an endogenous TLR2 ligand that mediates inflammatory and angiogenic mechanisms, https://ard.bmj.com/content/75/7/1392
• The Leptin System in Patients with Classical Galactosaemia - Putative Role and Clinical Consequences, https://esmed.org/MRA/mra/article/view/391/191
• Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node‐negative breast cancer patients, https://febs.onlinelibrary.wiley.com/doi/epdf/10.1111/febs.13354
• TRIF-Mediated TLR3 and TLR4 Signaling Is Negatively Regulated by ADAM15, https://journals.aai.org/jimmunol/article/190/5/2217/6328/TRIF-Mediated-TLR3-and-TLR4-Signaling-Is
• Nuclear factor κB subunits RelB and cRel negatively regulate Toll-like receptor 3-mediated β-interferon production via induction of transcriptional repressor protein YY1, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322859/pdf/zbc10977.pdf

• Gaucher Leadership Forum
• Osteoarthritis Research Society International
• Irish Society for Immunology
• Irish Endocrine Society
• Irish Cancer Society